In this week’s video, Dr. Brian GM Durie explains how to determine if monoclonal protein spikes in the blood are actually spikes due to daratumumab therapy.

BOTTOM LINE:

When assessing response, ensure that a monoclonal protein spike is not a dara spike with the proper tests.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
Daratumumab in the News Again: Showing Benefit in Frontline and at Relapse
Next Post
Closing or Halting of Myeloma Immune Therapy Trials: A Major Setback for Patients and Drug Companies

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.